202 related articles for article (PubMed ID: 8627566)
1. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
[TBL] [Abstract][Full Text] [Related]
2. The peripheral NK-1/NK-2 receptor antagonist MDL 105,172A inhibits tachykinin-mediated respiratory effects in guinea-pigs.
Kudlacz EM; Knippenberg RW; Shatzer SA; Kehne JH; McCloskey TC; Burkholder TP
J Auton Pharmacol; 1997 Apr; 17(2):109-19. PubMed ID: 9234081
[TBL] [Abstract][Full Text] [Related]
3. Effect of MDL 105,212, a nonpeptide NK-1/NK-2 receptor antagonist in an allergic guinea pig model.
Kudlacz EM; Knippenberg RW; Logan DE; Burkholder TP
J Pharmacol Exp Ther; 1996 Nov; 279(2):732-9. PubMed ID: 8930178
[TBL] [Abstract][Full Text] [Related]
4. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
[TBL] [Abstract][Full Text] [Related]
8. Novel triple neurokinin receptor antagonist CS-003 inhibits respiratory disease models in guinea pigs.
Tsuchida H; Takahashi S; Nosaka E; Kuraya T; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 Oct; 596(1-3):153-9. PubMed ID: 18706408
[TBL] [Abstract][Full Text] [Related]
9. Use of selective antagonists for further characterization of tachykinin NK-2, NK-1 and possible "septide-selective" receptors in guinea pig bronchus.
Zeng XP; Burcher E
J Pharmacol Exp Ther; 1994 Sep; 270(3):1295-300. PubMed ID: 7523658
[TBL] [Abstract][Full Text] [Related]
10. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist.
Cialdai C; Tramontana M; Patacchini R; Lecci A; Catalani C; Catalioto RM; Meini S; Valenti C; Altamura M; Giuliani S; Maggi CA
Eur J Pharmacol; 2006 Nov; 549(1-3):140-8. PubMed ID: 16979621
[TBL] [Abstract][Full Text] [Related]
11. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
12. Evidence for adrenergic and tachykinin activity in venom of the stonefish (Synanceja trachynis).
Hopkins BJ; Hodgson WC; Sutherland SK
Toxicon; 1996 May; 34(5):541-54. PubMed ID: 8783449
[TBL] [Abstract][Full Text] [Related]
13. SCH 206272: a potent, orally active tachykinin NK(1), NK(2), and NK(3) receptor antagonist.
Anthes JC; Chapman RW; Richard C; Eckel S; Corboz M; Hey JA; Fernandez X; Greenfeder S; McLeod R; Sehring S; Rizzo C; Crawley Y; Shih NY; Piwinski J; Reichard G; Ting P; Carruthers N; Cuss FM; Billah M; Kreutner W; Egan RW
Eur J Pharmacol; 2002 Aug; 450(2):191-202. PubMed ID: 12206858
[TBL] [Abstract][Full Text] [Related]
14. Role of nitric oxide and septide-insensitive NK(1) receptors in bronchoconstriction induced by aerosolised neurokinin A in guinea-pigs.
Ricciardolo FL; Trevisani M; Geppetti P; Nadel JA; Amadesi S; Bertrand C
Br J Pharmacol; 2000 Mar; 129(5):915-20. PubMed ID: 10696090
[TBL] [Abstract][Full Text] [Related]
15. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.
McLean S; Ganong A; Seymour PA; Snider RM; Desai MC; Rosen T; Bryce DK; Longo KP; Reynolds LS; Robinson G
J Pharmacol Exp Ther; 1993 Oct; 267(1):472-9. PubMed ID: 7693914
[TBL] [Abstract][Full Text] [Related]
16. Effects of FK224, a novel compound NK1 and NK2 receptor antagonist, on airway constriction and airway edema induced by neurokinins and sensory nerve stimulation in guinea pigs.
Murai M; Morimoto H; Maeda Y; Kiyotoh S; Nishikawa M; Fujii T
J Pharmacol Exp Ther; 1992 Jul; 262(1):403-8. PubMed ID: 1378097
[TBL] [Abstract][Full Text] [Related]
17. The effect of inhaled FK224, a tachykinin NK-1 and NK-2 receptor antagonist, on neurokinin A-induced bronchoconstriction in asthmatics.
Joos GF; Van Schoor J; Kips JC; Pauwels RA
Am J Respir Crit Care Med; 1996 Jun; 153(6 Pt 1):1781-4. PubMed ID: 8665034
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
[TBL] [Abstract][Full Text] [Related]
19. Effect of melatonin on the vasopressin secretion as influenced by tachykinin NK-1 receptor agonist and antagonist: in vivo and in vitro studies.
Juszczak M; Boczek-Leszczyk E; Stempniak B
J Physiol Pharmacol; 2007 Dec; 58(4):829-43. PubMed ID: 18195491
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.
Gerspacher M; Lewis C; Ball HA; Howes C; Subramanian N; Ryffel K; Fozard JR
J Med Chem; 2003 Jul; 46(16):3508-13. PubMed ID: 12877589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
